Ezt az oldalt automatikusan lefordították, és a fordítás pontossága nem garantált. Kérjük, olvassa el a angol verzió forrásszöveghez.

Safety and Immunogenicity Study of IP-QSV Vaccine in Healthy Adults/Adolescents, Children and Infants

2026. június 21. frissítette: International Vaccine Institute

A Phase 1/2a, Randomized, Observer-blind, Age-descending, Dose Finding Study to Evaluate the Safety and Immunogenicity of Institut Pasteur Quadrivalent Shigella Vaccine (IP-QSV) for Intramuscular Administration in Healthy Adults/Adolescents, Children and Infants

The goal of this phase 1/2a, randomized, observer-blind, age-descending, dose-finding trial is to evaluate the safety and immunogenicity of a quadrivalent synthetic oligosaccharide-based Shigella vaccine (adjuvanted IP-QSV) in adults, children, and infants in Mali. This first-in-human study is intended to obtain initial data on the safety of the adjuvanted IP-QSV vaccine and its effect on immune responses in a Shigella-endemic region.

A tanulmány áttekintése

Részletes leírás

this is phase 1/2a, randomized, observer-blind, age-descending, dose-finding trial to evaluate the safety and immunogenicity of a quadrivalent synthetic oligosaccharide-based Shigella vaccine (adjuvanted IP-QSV) in adults, children, and infants in Mali

A total of 370 healthy participants aged 6 months to 45 years in Mali will be enrolled and randomly assigned in a 2:1 or 2:2:1 ratio. The study groups are as follow

  • Group A (18-45 years): one dose of 30 µg IP / placebo in a 2:1 ratio
  • Group B (2-5 years): two doses of 10 µg IP / placebo administered 3 months apart in a 2:1 ratio
  • Group C (2-5 years): one dose of 30 µg IP / placebo in a 2:1 ratio
  • Group D (6-8 months): three doses of 2 µg IP / placebo administered at 3- and 6-month intervals in a 2:1 ratio
  • Group E (6-8 months): three doses of 10 µg IP or placebo administered at 3- and 6-month intervals in a 2:2:1 ratio
  • Group F (9-11 months): two doses of 10 µg IP / placebo administered 6 months apart in a 2:1 ratio
  • Group G (6-8 months): two doses of 30 µg IP or placebo administered 9 months apart in a 2:1 ratio.

The DSMB must review the safety data of each group and approve study continuation before investigational product administration of the next group is initiated.

Participants will attend between 5 and 11 scheduled study visits, including blood sampling for immunogenicity assessments and safety evaluations. Blood samples will be collected at screening and at multiple time points throughout the study to assess immune responses and overall health status. Baseline laboratory assessments will include HIV testing, hepatitis screening, complete blood counts, and renal and liver function tests. Women of childbearing potential will undergo pregnancy testing at screening.

Serious adverse events (SAEs) will be reported and followed until resolution or stabilization. Participants will be instructed to contact the study team immediately if they experience any serious adverse event.

The study will monitor for SAEs, including hospitalization, death, or significant disability, occurring during the study, regardless of whether they are considered related to the study vaccine. Immediate reactions occurring within 0.5 - 1 hours after vaccination will be monitored to detect allergic or other acute responses. Solicited mild to moderate adverse events, such as nausea, fever, and diarrhea, will be recorded for up to 7 days after each vaccination.

Tanulmány típusa

Beavatkozó

Beiratkozás (Becsült)

370

Fázis

  • 2. fázis
  • 1. fázis

Kapcsolatok és helyek

Ez a rész a vizsgálatot végzők elérhetőségeit, valamint a vizsgálat lefolytatásának helyére vonatkozó információkat tartalmazza.

Tanulmányi kapcsolat

Részvételi kritériumok

A kutatók olyan embereket keresnek, akik megfelelnek egy bizonyos leírásnak, az úgynevezett jogosultsági kritériumoknak. Néhány példa ezekre a kritériumokra a személy általános egészségi állapota vagy a korábbi kezelések.

Jogosultsági kritériumok

Tanulmányozható életkorok

  • Gyermek
  • Felnőtt

Egészséges önkénteseket fogad

Igen

Leírás

Inclusion Criteria:

  • Individuals aged 18-45 years in Group A, 2-5 years in Groups B and C, 6-8 months in Groups D, E and G , and 9-11 months in Group F
  • Participants/ Participants' Legally Acceptable representative (LAR) willing to provide written informed consent to participate in the study voluntarily
  • Participants who can comply with the study requirements
  • Individuals in good health as determined by the outcome of medical history, physical examination, and the clinical judgment of the investigator

Exclusion Criteria:

  • Known history or allergy to investigational vaccine components or other medications, or any other allergies deemed by the investigator to increase the risk of an adverse event if they were to participate in the trial
  • Individuals with major congenital abnormalities, developmental disorders, genetic defects, or severe malnutrition, among other conditions which in the opinion of investigator may affect the participant's participation in the study
  • Known history of immune function disorders including immunodeficiency diseases (known HIV infection¥ or other immune function disorders) which in the opinion of investigator may affect the participant's participation in the study or interfere with the assessment of the study objectives
  • Use of systemic steroids within past 6 months (>10 mg/day prednisone equivalent for periods exceeding 2 consecutive weeks), or receive chemotherapy, radiation therapy or other immunosuppressive drugs within the past 6 months
  • Any abnormality or chronic disease which in the opinion of the investigator might be detrimental for the safety of the participant and interfere with the assessment of the study objectives
  • Individuals with behavioral or cognitive impairment or psychiatric disease or neural disorders that, in the opinion of the investigator, could interfere with the participant's ability to participate in the trial
  • Individuals with splenectomy
  • Individuals with a known bleeding diathesis, or any condition that may be associated with a prolonged bleeding time resulting in contraindication for IM injections/blood extractions
  • Receipt of blood, blood-derived products, or immunoglobulin products in the past 3 months
  • Individuals who have received other vaccines from 4 weeks prior to the first dose of investigational product administration or planned to receive any vaccine within 4 weeks post any dose of the investigational product
  • Individuals with active or known previous culture-proven Shigella infection
  • Individuals who have household contact with/and /or intimate exposure to an individual with laboratory confirmed Shigella infection
  • Previous participation in any study in which a Shigella-vaccine candidate was administered
  • Individuals with a history of severe diarrhea in the last 6 months requiring care at a medical facility lasting 24 hours or more
  • Individuals with a history of clinically significant gastrointestinal disorders or with any history of frequent diarrhea, nausea or emesis, within the last 6 months
  • Individuals aged below 5 years with Weight for Height Z score and/or Height for Age Z score of less than -3
  • Any female participant who is lactating or pregnant#
  • Females of childbearing potential who do not agree to use an effective birth control method* for at least 4 weeks before the screening and up to 12 weeks after the investigational product administration
  • Individuals enrolled in another clinical trial within 6 months prior to enrollment, concomitantly enrolled or scheduled to be enrolled in another trial during study period
  • Individuals who are research staff involved with the clinical trial or household members of research staff
  • As per Investigator's medical judgement, an individual could be excluded from the study despite meeting all inclusion/exclusion criteria mentioned above
  • Special Conditions for Children Aged 24 Months and Below: For such children, additional exclusion criteria include difficult birth, resuscitation after suffocation, a history of neurological damage, premature birth (delivery before the 37th week of gestation), and low birth weight (less than 2500 grams)
  • Clinically significant abnormal findings in blood tests during the screening

Tanulási terv

Ez a rész a vizsgálati terv részleteit tartalmazza, beleértve a vizsgálat megtervezését és a vizsgálat mérését.

Hogyan készül a tanulmány?

Tervezési részletek

  • Elsődleges cél: Megelőzés
  • Kiosztás: Véletlenszerűsített
  • Beavatkozó modell: Szekvenciális hozzárendelés
  • Maszkolás: Négyszeres

Fegyverek és beavatkozások

Résztvevő csoport / kar
Beavatkozás / kezelés
Kísérleti: Group A
A total of 30 participants aged 18-45 years will receive one dose of 30 µg IP-QSV or placebo.
A mix of the four synthetic OS-based conjugates, each independently targeting SF 2a, 3a, 6, or Sson, and using tetanus toxoid as carrier protein. 30 ㎍ of IP-QSV adjuvanted with Aluminum phosphate.
Sterile 0.9% sodium chloride.
Kísérleti: Group B
A total of 30 participants aged 2-5 years will receive two doses of 10 µg IP-QSV or placebo at 3 months interval.
Sterile 0.9% sodium chloride.
A mix of the four synthetic OS-based conjugates, each independently targeting SF 2a, 3a, 6, or Sson, and using tetanus toxoid as carrier protein. 30 ㎍ of IP-QSV adjuvanted with Aluminum phosphate.
Kísérleti: Group C
A total of 30 participants aged 2-5 years will receive one dose of 30 µg IP-QSV or placebo
A mix of the four synthetic OS-based conjugates, each independently targeting SF 2a, 3a, 6, or Sson, and using tetanus toxoid as carrier protein. 30 ㎍ of IP-QSV adjuvanted with Aluminum phosphate.
Sterile 0.9% sodium chloride.
Placebo Comparator: Group D
A total of 60 participants aged 6-8 months will receive three doses of 2 µg IP-QSV or placebo at Months 0, 3, and 9.
Sterile 0.9% sodium chloride.
A mix of the four synthetic OS-based conjugates, each independently targeting SF 2a, 3a, 6, or Sson, and using tetanus toxoid as carrier protein. 30 ㎍ of IP-QSV adjuvanted with Aluminum phosphate.
Kísérleti: Group E
A total of 100 participants aged 6-8 months will receive three doses of 10 µg IP-QSV or placebo at Months 0, 3, and 9.
Sterile 0.9% sodium chloride.
A mix of the four synthetic OS-based conjugates, each independently targeting SF 2a, 3a, 6, or Sson, and using tetanus toxoid as carrier protein. 30 ㎍ of IP-QSV adjuvanted with Aluminum phosphate.
Kísérleti: Group F
A total of 60 participants aged 9-11 months will receive two doses of 10 µg IP-QSV or placebo at 6 months interval
Sterile 0.9% sodium chloride.
A mix of the four synthetic OS-based conjugates, each independently targeting SF 2a, 3a, 6, or Sson, and using tetanus toxoid as carrier protein. 30 ㎍ of IP-QSV adjuvanted with Aluminum phosphate.
Kísérleti: Group G
A total of 60 participants aged 6-8 months will receive two doses of 30 µg IP-QSV or placebo at 9 months interval
A mix of the four synthetic OS-based conjugates, each independently targeting SF 2a, 3a, 6, or Sson, and using tetanus toxoid as carrier protein. 30 ㎍ of IP-QSV adjuvanted with Aluminum phosphate.
Sterile 0.9% sodium chloride.

Mit mér a tanulmány?

Elsődleges eredményintézkedések

Eredménymérő
Intézkedés leírása
Időkeret
Kért nemkívánatos események
Időkeret: Minden adag után 7 napon belül
A kért injekció beadásának helye és a kért szisztémás nemkívánatos események előfordulása minden vizsgálati vakcinázás időpontjától az egyes vizsgálati vakcinázást követő 7 napig
Minden adag után 7 napon belül
Nem kívánt nemkívánatos események
Időkeret: Minden adag után 28 napon belül
Nemkívánatos nemkívánatos események előfordulása az egyes vizsgálati vakcinázások időpontjától az egyes vizsgálati vakcinázások utáni 28 napig.
Minden adag után 28 napon belül
Súlyos mellékhatások (SAE-k), különleges jelentőségű mellékhatások (AESI-k) és orvosi ellátást igénylő mellékhatások (MAAE-k)
Időkeret: a vizsgálat befejezéséig, átlagosan 6 hónap
Bármely SGA / AESI / MAAE előfordulása az első oltási adagtól a vizsgálat utolsó látogatásáig
a vizsgálat befejezéséig, átlagosan 6 hónap
Azonnali mellékhatások
Időkeret: Az egyes adagok beadását követő 30 percen belül
Azonnali mellékhatások előfordulása az egyes dózisok beadását követő 30 percen belül
Az egyes adagok beadását követő 30 percen belül
GMT of serum IgG against SF 2a, SF3a, SF6 & Sson LPS at 4 weeks and at 6 months post primary IP administration of IP-QSV 2/10/30μg OS-equivalent dosages in infants aged 6-8 months
Időkeret: Baseline, at 4 weeks, and at 6 months post primary IP administration series
GMT of serum IgG antibodies to SF2a, SF3a, SF6 & Sson LPSs (for each one of the four serotypes and combined serotypes (SF all)), after 2-dose primary series (0-3-month) of 2μg of IP-QSV / placebo, or 2-dose primary series (0-3-month) of 10μg of IP-QSV / placebo, or Single primary dose of 30μg of IP-QSV / placebo
Baseline, at 4 weeks, and at 6 months post primary IP administration series
Seroconversion of serum IgG against SF 2a, SF3a, SF6 & Sson LPS at 4 weeks and at 6 months post primary IP administration of IP-QSV 2/10/30μg OS-equivalent dosages in infants aged 6-8 months
Időkeret: at 4 weeks and at 6 months post primary IP administration series
Percentage of seroconversion (defined as at least a 4-fold increase in anti-LPS IgG titer from baseline) for each one of the four serotypes and combined serotypes (SF2a, SF3a, SF6, Sson LPSs, SF all), after 2-dose primary series (0-3-month) of 2μg of IP-QSV / placebo or 2-dose primary series (0-3-month) of 10μg of IP-QSV / placebo or Single primary dose of 30μg of IP-QSV / placebo
at 4 weeks and at 6 months post primary IP administration series

Másodlagos eredményintézkedések

Eredménymérő
Intézkedés leírása
Időkeret
GMT of serum IgG against SF 2a, SF3a, SF6 & Sson LPS at 4 weeks and at 6 months post full IP administration of IP-QSV 2/10/30μg OS-equivalent dosages in infants aged 6-8 months
Időkeret: Baseline, at 4 weeks, and at 6 months post full IP administration series
GMT of serum IgG antibodies to SF2a, SF3a, SF6 & Sson LPSs, (for each one of the four serotypes and combined serotypes (SF all)), after 3 doses(0-3-9-month) of 2μg IP-QSV / placebo, or 3 doses ( 0-3-9-month) of 10μg IP-QSV / placebo, or 2 doses ( 0-9-month) of 30μg IP-QSV / placebo
Baseline, at 4 weeks, and at 6 months post full IP administration series
Seroconversion of serum IgG against SF 2a, SF3a, SF6 & Sson LPS at 4 weeks and at 6 months post full IP administration of IP-QSV 2/10/30μg OS-equivalent dosages in infants aged 6-8 months
Időkeret: Baseline, at 4 weeks, and at 6 months post full IP administration series
Percentage of seroconversion (defined as at least a 4-fold increase in anti-LPS IgG titer from baseline) for each one of the four serotypes (SF2a, SF3a, SF6 & Sson LPSs, and combined serotypes (SF, all)), after 3 doses ( 0-3-9-month) of 2μg IP-QSV / placebo, or 3 doses ( 0-3-9-month)of 10μg IP-QSV / placebo, or 2 doses ( 0-9-month) of 30μg IP-QSV / placebo
Baseline, at 4 weeks, and at 6 months post full IP administration series
GMT of serum IgG against SF 2a, SF3a, SF6 & Sson LPS at 4 weeks post each dose of full IP administration series and at 6 months post full IP administration of IP-QSV 10μg OS-equivalent dosages in infants aged 9-11 month
Időkeret: Baseline and at post each dose of full IP administration series
GMT of serum IgG antibodies to SF2a, SF3a, SF6 & Sson LPSs(for each one of the four serotypes and combined serotypes (SF, all)), at 4 weeks after 1 and 2 doses ( 0-6-month) of 10μg of IP-QSV / placebo
Baseline and at post each dose of full IP administration series
Seroconversion of serum IgG against SF 2a, SF3a, SF6 & Sson LPS at 4 weeks post each dose of full IP administration series and at 6 months post full IP administration of IP-QSV 10μg OS-equivalent dosages in infants aged 9-11 months
Időkeret: at post each dose of full IP administration series
Percentage of Seroconversion (defined as at least a 4-fold increase in anti-LPS IgG titer from baseline) for each one of the four serotypes (SF2a, SF3a, SF6 & Sson LPSs, and combined serotypes (SF, all)) at 4 weeks after 1 and 2 doses in 0-6-month dose schedule of 10μg IP-QSV / placebo
at post each dose of full IP administration series
GMT of SF2a, SF3a, SF6 & Sson -specific serum bactericidal antibodies (SBA) at 4 weeks and at 6 months post primary IP and full IP administration of IP-QSV 2/10/30μg OS-equivalent dosages in infants aged 6-11 months
Időkeret: Baseline, at 4 weeks and at 6 months post primary and full IP administration series
GMT of SBA to SF2a, SF3a, SF6 & Sson, independently for each one of the four serotypes and combined serotypes (SF, all), after 2-dose primary series (0-3-month) of 2/10μg of IP-QSV / placebo in infants aged 6-8 months, or Single primary dose of 30μg of IP-QSV / placebo in infants aged 6-8 months, or 3 doses in 0-3-9-month dose schedule of 2/10μg IP-QSV / placebo in infants aged 6-8 months, or Single primary dose of 10μg of IP-QSV / placebo in infants aged 9-11 months, or 2 doses in 0-6-month dose schedule of 10μg IP-QSV / placebo in infants aged 9-11 months, or 2 doses in 0-9-month dose schedule of 30μg IP-QSV / placebo in infants aged 6-8 months
Baseline, at 4 weeks and at 6 months post primary and full IP administration series
Seroconversion of SF2a, SF3a, SF6 & Sson -specific serum bactericidal antibodies (SBA) at 4 weeks and at 6 months post primary IP and full IP administration of IP-QSV 2/10/30μg OS-equivalent dosages in infants aged 6-11 months
Időkeret: at 4 weeks and at 6 months post primary and full IP administration series
Percentage of seroconversion of SBA to SF2a, SF3a, SF6 & Sson, independently for each one of the four serotypes and combined serotypes (SF, all), after 2-dose primary series (0-3-month) of 2/10μg of IP-QSV / placebo in infants aged 6-8 months, or Single primary dose of 30μg of IP-QSV / placebo in infants aged 6-8 months, or 3 doses in 0-3-9-month dose schedule of 2/10μg IP-QSV / placebo in infants aged 6-8 months, or Single primary dose of 10μg of IP-QSV / placebo in infants aged 9-11 months, or 2 doses in 0-6-month dose schedule of 10μg IP-QSV / placebo in infants aged 9-11 months, or 2 doses in 0-9-month dose schedule of 30μg IP-QSV / placebo in infants aged 6-8 months
at 4 weeks and at 6 months post primary and full IP administration series
GMT of serum IgG against SF2a, SF3a, SF6 & Sson LPS at 4 weeks post each dose of full IP administration series of IP-QSV 10/30μg OS-equivalent dosages in adults aged 18-45 years and children aged 2-5 years
Időkeret: Baseline and at 4 weeks post each dose of full IP administration series
GMT of serum IgG antibodies to SF2a, SF3a, SF6 & Sson, and percentage of seroconversion, after 1 dose of 30μg in adults aged 18-45 years and in children aged 2-5 years or after each dose of 10μg in 0-3mo dose schedule in children aged 2-5 years
Baseline and at 4 weeks post each dose of full IP administration series
Seroconversion of serum IgG against SF2a, SF3a, SF6 & Sson LPS at 4 weeks post each dose of full IP administration of IP-QSV 10/30μg OS-equivalent dosages in adults aged 18-45 years and children aged 2-5 years
Időkeret: at 4 weeks post each dose of full IP administration series
Percentage of seroconversion of serum IgG antibodies to SF2a, SF3a, SF6 & Sson, after 1 dose of 30μg in adults aged 18-45 years and in children aged 2-5 years or after each dose of 10μg in 0-3mo dose schedule in children aged 2-5 years
at 4 weeks post each dose of full IP administration series

Együttműködők és nyomozók

Itt találhatja meg a tanulmányban érintett személyeket és szervezeteket.

Együttműködők

Nyomozók

  • Kutatásvezető: Samba Sow, MD, CVD-Mali

Tanulmányi rekorddátumok

Ezek a dátumok nyomon követik a ClinicalTrials.gov webhelyre benyújtott vizsgálati rekordok és összefoglaló eredmények benyújtásának folyamatát. A vizsgálati feljegyzéseket és a jelentett eredményeket a Nemzeti Orvostudományi Könyvtár (NLM) felülvizsgálja, hogy megbizonyosodjon arról, hogy megfelelnek-e az adott minőség-ellenőrzési szabványoknak, mielőtt közzéteszik őket a nyilvános weboldalon.

Tanulmány főbb dátumok

Tanulmány kezdete (Becsült)

2026. július 1.

Elsődleges befejezés (Becsült)

2027. augusztus 1.

A tanulmány befejezése (Becsült)

2028. november 1.

Tanulmányi regisztráció dátumai

Először benyújtva

2025. december 6.

Először nyújtották be, amely megfelel a minőségbiztosítási kritériumoknak

2026. június 21.

Első közzététel (Tényleges)

2026. június 24.

Tanulmányi rekordok frissítései

Utolsó frissítés közzétéve (Tényleges)

2026. június 24.

Az utolsó frissítés elküldve, amely megfelel a minőségbiztosítási kritériumoknak

2026. június 21.

Utolsó ellenőrzés

2026. június 1.

Több információ

A tanulmányhoz kapcsolódó kifejezések

Terv az egyéni résztvevői adatokhoz (IPD)

Tervezi megosztani az egyéni résztvevői adatokat (IPD)?

NEM

Gyógyszer- és eszközinformációk, tanulmányi dokumentumok

Egy amerikai FDA által szabályozott gyógyszerkészítményt tanulmányoz

Nem

Egy amerikai FDA által szabályozott eszközterméket tanulmányoz

Nem

Ezt az információt közvetlenül a clinicaltrials.gov webhelyről szereztük be, változtatás nélkül. Ha bármilyen kérése van vizsgálati adatainak módosítására, eltávolítására vagy frissítésére, kérjük, írjon a következő címre: register@clinicaltrials.gov. Amint a változás bevezetésre kerül a clinicaltrials.gov oldalon, ez a webhelyünkön is automatikusan frissül. .

Iratkozz fel